Get Permission Abraham, Daddibavi, Bhandari, Palatty, Baliga, and Jakribettu: Clinicohematological and drug prescription details in children affected with malaria: A retrospective study from a tertiary hospital of an endemic region in India


Introduction

Malaria is a parasitic infection caused by Plasmodium species, transmitted by the bite of an infected female Anopheles mosquito. Humans are infected by mainly four Plasmodium species i.e., P. falciparum, P. vivax, P. malariae and P. ovale.1 Malaria is endemic in many parts of the world and reports suggest that 228 million cases were diagnosed worldwide in the year 2018.2 In India, 0.4 million cases were reported in 2018, majority of cases were from states with forest, hilly and tribal areas like Odisha, Chattisgarh, Jharkhand, Madhya Pradesh, Maharashtra in the central part of India and Tripura, Meghalaya and Mizoram in the eastern part of the country.3 The state of Karnataka, reported 8174 cases in 2018, of which 86% (7042) were from the district of Dakshina Kannada alone.4

Clinically, malaria is a preventable and curable disease, but can be life-threatening, if not diagnosed and treated on time. Most of the cases present with malarial paroxysm with typical high grade fever with chills and rigor, anemia and hepatosplenomegaly.2 Complications like black water fever, cerebral malaria are commonly seen with P. falciparum, whereas relapse is common in P. vivax due to activation of hypnozoites in liver cells.5, 6

Malaria is a serious disease in the pediatric age group. It is estimated that at a global level in the year 2018, 405,000 deaths were due to malaria and that 272,000 were in the most vulnerable population the children under the age of five.2 In Sub - Saharan Africa alone, the burden of the P. falciparium infection in children is as high as 24 million according to the World Health Organization report.2 The principal reason is that being intra-erythrocytic parasite, malaria is known to cause major derangement in hematological parameters mainly RBC, WBC and platelets.5 Severe anemia, leukopenia and thrombocytopenia are very well documented in falciparum malaria. 6, 7, 8, 9, 10 Further, all major organs like the brain, liver and renal can be affected by malaria, patients with hepatorenal dysfunction have poor prognosis. 11

A literature study suggests that the clinicohematological and treatment details of malaria caused by the different species have not been reported. Therefore, in this study, an attempt was made to understand the changes in laboratory parameters like haematology, hepato-renal among the paediatric malaria patients at a tertiary centre in Coastal Karnataka, India, which is documented to be an endemic region in India and the world.

Materials and Methods

The study was approved by the institutional ethics committee of Father Muller Charitable Institute (FMMCIEC/CCM/292/18). The inclusion criteria included all paediatric patients (<18 years of age) who were diagnosed with malaria during the study period (January 2015 to December 2018). The exclusion criteria were children infected with other acute infections (like dengue, leptospirosis, typhoid, tuberculosis and other bacterial, protozoal and viral infections), children suffering from cancers and blood disorders. Children having malaria and other co-infection were also not considered. By Diagnosis of malaria was established by staining a peripheral smear geimsa stain or by QBC test according to availability. All the other laboratory parameters were collected from the medical records of these children diagnosed of malaria. In addition to the haematological and biochemical data of age matched children who had come for nonspecific viral fevers, non-infectious dermatological issues were used as control to ascertain the quantitative difference between the controls verses the study group. The data collected were entered in Microsoft Excel and statistical analysis was done. The mean, standard deviation were done for all the parameters and compared with control cases, using ANOVA / Kruskal wallis test. The p value < 0.05 were considered as significant.

Results

A total of 290 children (males 182: females 108, 2:1) were diagnosed with malaria during the study period. Among them, 204 (70.3%) patients had P. vivax, followed by mixed malaria 71 (24.5%) and 15 (5.2%) had P. falciparum and these three categories were compared with control cases. The majority of the patients (179, 61.72%) belonged to the age group of 11-16 years (Table 1). There was no death reported among any children during the study period. Among the 290 children diagnosed with malaria, all had fever. Vomiting (89, 30.7%) was second most common symptom followed by headache (57, 19.7%) and convulsions (39, 13.6%) as shown in Table 1. Jaundice was observed only in 1 patient with mixed malaria.

Among the haematological parameters, the haemoglobin level was least in group with mixed malaria compared to others (Table 2). There was significant lower total leucocyte count in all categories compared to controls. Among the differential leucocyte counts, there was significant lower lymphocyte, eosinophil with higher monocyte counts among the malaria groups. There was significant difference in differential neutrophil count. The Erythrocyte Sedimentation Rate (ESR) was significantly higher in the infected cases. There was significant thrombocytopenia seen mainly in Falciparum group compared to mixed and vivax in decreasing order. The liver function was deranged significantly. The total bilirubin, and conjugated bilirubins were increased, significantly higher in mixed group.(Table 3) The liver enzymes were elevated, but reported to be higher in falciparum group. No significant difference was seen in AST / ALT ratio. The parameters of the renal system like urea were significantly higher in mixed malaria compared to other groups. The derangement in electrolytes seen was mainly hyponatremia, hypokalemia and hypochloremia. There was no significant difference in creatinine value in among the three infected groups.

Table 1

Distribution of symptoms among the children diagnosed with malaria.

Symptoms

Vivax (N=204)

Falciparum (N=15)

Mixed (N=71)

Total (N=290)

Number

%

Number

%

Number

%

Number

%

Gender

Male

131

64.22

12

80.00

39

54.93

182

62.76

Female

73

35.78

3

20.00

32

45.07

108

37.24

Age (in years)

01-05

38

18.63

4

26.67

16

22.54

58

20.00

06-10

34

16.67

5

33.33

14

19.72

53

18.28

11-16

132

64.71

6

40.00

41

57.75

179

61.72

Symptoms

Fever

204

100

15

100.00

71

100

290

100

Vomiting

57

27.94

7

46.67

25

35.21

89

30.69

Headache

43

21.08

4

26.67

10

14.08

57

19.66

Convulsions

27

13.24

2

13.33

10

14.08

39

13.45

Abdominal Pain

13

6.37

1

6.67

-

-

14

4.83

Body ache

3

1.47

1

6.67

5

7.04

9

3.10

Jaundice

0

0.00

0

0.00

1

1.41

1

0.34

Table 2

Comparison of blood cell parameters among the healthy and different malaria infections in children.

Type

Mean ± Std. Dev

Post hoc analysis p with Bonferroni correction

Median (IQR)

ANOVA /Kruskal wallis test p value

Hb

Control

12.59±1.44

12.5(11.6-13.4)

0.0001 HS

Vivax

11.25±1.9

0.0001

11.45(10.2-12.33)

Falciparum

12.04±2.54

1.000

11.8(10.7-14.4)

Mixed

10.9±2.35

0.0001

11.3(9.4-12.3)

TC

Control

7903.22±2790.1

7800(5500-10200)

0.0001 HS

Vivax

6362.84±3090.1

0.002

6000(4200-7600)

Falciparum

6557.14±4047.74

.883

5650(3725-7275)

Mixed

6764.18±3837.05

.180

5600(4200-8300)

N

Control

61.87±10.52

63(54-70)

0.560 NS

Vivax

62.89±15.93

1.000

65.5(53-75)

Falciparum

61.4±13.82

1.000

65(48-69)

Mixed

60.12±18.36

1.000

64(49-74)

L

Control

33.17±9.77

32(26-40)

0.0001 HS

Vivax

26.68±15.75

006

23(15-37)

Falciparum

28.13±15.17

1.000

22(18-39)

Mixed

29.49±18.18

.781

25.5(14.25-41.5)

M

Control

2.22±1.18

2(1-3)

0.0001 HS

Vivax

8.43±4.55

0.0001

9(6-12)

Falciparum

8.36±5.26

0.0001

10(3.75-12)

Mixed

9.07±4.21

0.0001

10(6-12)

E

Control

2.86±2.19

2(1-5)

0.0001 HS

Vivax

1.76±2.08

0.0001

1(1-2)

Falciparum

1.13±0.64

0.011

1(1-2)

Mixed

1.66±1.49

0.001

1(1-1)

[i] Hb- Heamoglobin(g%), TC - Total Leucocyte count (in cu.mm), N- Neutrophils (%), L- Lymphocytes (%), M- Monocytes (%), Eosinophils (%), HS- Highly significant, NS- Not significant.

Table 3

Comparison of hematological parameters among the healthy and different malarial infections in children

Type

Mean±Std. Dev

Post hoc analysis p with Bonferroni correction

Median (IQR)

ANOVA /Kruskal wallis test p value

Platlets

Control

231125±80041.35

219000(163250-302500)

0.0001 HS

Vivax

102197.6±70504.14

0.0001

92000(63750-121000)

Falciparum

93294.12±51191.75

0.0001

86000(59000-110000)

Mixed

97014.29±64925.49

0.0001

83500(56250-124750)

ESR

Control

9.25±3.62

9(6-11)

0.0001 HS

Vivax

23.71±19.57

0.0001

18(10-31)

Falciparum

19.63±13.62

.607

15.5(9.25-32)

Mixed

21.7±19.47

0.003

16.5(9-29)

CRP

Control

3.51±2.5

2.76(1.07-5.41)

0.0001 HS

Vivax

65.99±53.15

0.0001

53.53(27.18-88.45)

Falciparum

72.78±103.23

0.0001

28.57(10.11-179.67)

Mixed

58.57±58.34

0.0001

38.27(22.44-72.37)

PCV

Control

40.05±4.02

39.45(36.78-43.03)

0.0001 HS

Vivax

34.86±5.51

0.0001

35(31.5-38.2)

Falciparum

38.96±6.09

1.000

40.3(33.3-44.7)

Mixed

33.61±6.97

0.0001

35.6(29.08-37.9)

MCV

Control

84.03±5.85

84.15(80.6-88.85)

0.0001 HS

Vivax

79.41±6.48

0.0001

80(74.3-83.75)

Falciparum

78.49±6.36

.172

77.6(76-81.9)

Mixed

78.48±6.14

0.0001

79.95(73.95-81.98)

MCH

Control

28.09±1.86

28.3(26.8-29.23)

0.001 HS

Vivax

27.06±3

.203

26.6(25-28.08)

Falciparum

26.99±2.44

1.000

26.5(25-29.3)

Mixed

26.32±2.96

0.021

26.3(24.08-27.7)

[i] Platelets (/cu.mm), ESR- Erythrocyte sedimentation rate (mm/1st hour), CRP- C Reactive protein (mg%), PCV - Packed cell volume (%), MCV- Mean Corpuscular Volume (fL), MCH- Mean Corpuscular Heamoglbin (pg/cell) ,HS- Highly significant

Table 4

Comparison of liver parameters among the healthy and different malarial infections in children

Type

Mean±Std. Dev

Post hoc analysis with Bonferroni correction

Median (IQR)

ANOVA /Kruskal wallis test p value

AST

Control

20.28±6.06

19(15.25-25)

0.0001 HS

Vivax

36.82±44.74

.203

24(19.25-33.75)

Falciparum

62.69±64.7

0.005

45(30-57)

Mixed

37.91±26.69

.343

30(19.5-50.5)

ALT

Control

16.67±8.04

14(11-19)

0.0001 HS

Vivax

26.21±27.39

.362

19(12-27)

Falciparum

45.00±33.56

0.007

37(24-54)

Mixed

33.11±33.89

0.036

20(14.5-43.5)

AST/ALT

Control

1.43±0.74

1.2(0.74-1.98)

0.887 NS

Vivax

1.44±0.56

1.000

1.31(1.07-1.8)

Falciparum

1.39±0.63

1.000

1.26(0.93-1.8)

Mixed

1.39±0.58

1.000

1.27(1.02-1.67)

TB

Control

0.61±0.4

0.5(0.35-0.7)

0.0001 HS

Vivax

1.27±1.41

0.050

1(0.71-1.32)

Falciparum

1.39±0.77

.357

1.3(0.82-1.58)

Mixed

1.87±2.13

0.002

0.95(0.53-2.16)

CB

Control

0.22±0.12

0.2(0.1-0.3)

0.0001 HS

Vivax

0.63±1.21

.402

0.4(0.29-0.55)

Falciparum

0.57±0.44

1.000

0.47(0.27-0.66)

Mixed

1.35±1.74

0.003

0.75(0.3-1.28)

UB

Control

0.35±0.24

0.3(0.2-0.4)

0.0001 HS

Vivax

0.71±0.42

0.002

0.63(0.43-0.83)

Falciparum

0.86±0.43

0.007

0.87(0.52-1.13)

Mixed

0.93±0.85

0.0001

0.5(0.37-1.36)

Alb

Control

4.28±0.47

4.36(3.91-4.55)

0.001 HS

Vivax

3.87±0.52

0.004

3.97(3.64-4.23)

Falciparum

3.78±0.53

0.049

4(3.5-4.29)

Mixed

3.8±0.66

0.015

3.92(3.25-4.32)

Glob

Control

2.97±0.36

3(2.7-3.28)

0.015 sig

Vivax

2.71±0.41

0.036

2.72(2.4-2.95)

Falciparum

2.85±0.4

1.000

2.78(2.47-3.3)

Mixed

2.74±0.57

.401

2.77(2.34-3.05)

A/G

Control

1.46±0.27

1.4(1.3-1.58)

0.512 NS

Vivax

1.46±0.28

1.000

1.46(1.27-1.68)

Falciparum

1.35±0.24

1.000

1.29(1.15-1.59)

Mixed

1.45±0.42

1.000

1.47(1.19-1.66)

[i] (AST -Serum Aspartate aminotransferase (IU/L),ALT- Serum Alanine Aminotransferase (IU/L), TB- Serum Total Bilirubin (mg%), CB-Serum Conjugated Bilirubin (mg%), UB -Serum Unconjugated Bilirubin (mg%), Alb -Blood Albumin (g%), Glob-Blood Globulin (g%), A/G - Albumin/ Globulin Ratio"), NS- Not significant, sig - significant, HS- Highly significant

Table 5

Comparison of renal parameters among the healthy and different malarial infections in children

Type

Mean±Std. Dev

Post hoc analysis with Bonferroni correction

Median (IQR)

ANOVA /Kruskal wallis test p value

Creatine

Control

0.75±0.25

0.7(0.5-0.9)

0.198 NS

Vivax

0.84±0.94

1.000

0.7(0.5-0.88)

Falciparum

0.85±0.23

1.000

0.82(0.73-0.93)

Mixed

1.05±1.32

.766

0.72(0.54-1.01)

Urea

Control

16.44±4.14

17(13-19)

0.0001 HS

Vivax

25.89±12.14

0.0001

23(19-30)

Falciparum

26.83±12.59

0.021

26(15.5-31.75)

Mixed

29.04±13.04

0.0001

28.5(20-36.75)

Na

Control

139.04±1.73

139.5(138-140)

0.0001 HS

Vivax

135.14±3.32

0.0001

135(133-137)

Falciparum

134.85±2.67

0.001

135(133.5-137)

Mixed

134.39±4.06

0.0001

134(133-137)

K

Control

4.28±0.36

4.26(4.04-4.5)

0.003 HS

Vivax

3.93±0.54

0.009

3.94(3.6-4.14)

Falciparum

4.1±0.56

1.000

4.04(3.66-4.35)

Mixed

3.91±0.51

0.032

3.87(3.5-4.4)

Cl

Control

101.6±2.2

101.35(100.1-103.3)

0.0001 HS

Vivax

96.83±10.3

0.04

97.7(94-101.3)

Falciparum

96.82±3.56

0.48

97.6(92.55-99.65)

Mixed

96.7±4.25

0.143

96.4(94.2-99.35)

[i] Creatinine - Serum Creatinine(mg%), urea- Blood Urea (mg%), Na- Serum Sodium (mEq/L), K -Serum Potassium (mEq/L), Cl- Serum Chloride (mEq/L), NS- Not significant, HS- Highly significant

Table 6

Antimalarial drugs administered to children diagnosed with malaria.

Medication administered

Vivax

Falciaprum

Mixed infection

Number

%

Number

%

Number

%

Chloroquine

187

91.67

-

-

Artermether

4

1.96

15

100

71

100

Cq+ Ar

13

6.37

-

-

Primaquine

204

100

15

100

71

100

When compared to controls, the acute phase protein, C reactive protein was significantly high in all the groups with, highest level was seen in falciparum group.(Table 4) In mixed malaria patients among the haematological parameters, it was observed that there was significant anaemia, monocytosis, reduced PCV, MCV, MCH, renal parameters like blood urea were increased and electrolytes were reduced.(Table 5) Among LFT, there was elevated bilirubin levels compared to other sub-group of patients. In Falciparum group, reduced eosinophil and platelets were observed among the haematological parameters and reduction in serum total protein, albumin, globulin and A/G ratio were observed. CRP was elevated significantly in this group. When compared with other groups, vivax malaria patients had significant leucocytosis, neutrophilia, lymphopenia and increased ESR.

Among the 204 Vivax group of patients, Chloroquine (187, 91.67%) was the most frequently administered drug, whereas Chloroquine artemether combination was prescribed in very few (13, 6.37%) patients (Table 6). Both Falciparum and mixed group were treated with Artemether. Anti-hypnozoites drug, ie Primaquine were administrated to all vivax and mixed malarial patients as per guidelines for 14 days.

Discussion

Malaria is a multisystem disorder, warranting hospitalization, appropriate antimalarial therapy and prevention of its complications. 12, 13, 14, 15 Plasmodium vivax was the most common causative agent followed by mixed malaria. Isolated Plasmodium falciparum infection was the least common protozoa among cases. Similar, epidemiological trend was noted over a decade where Plasmodium falciparum accounted for 6.8 to 30.9% of all cases. 16 Similar observations were made in a large cross-sectional surveillance of 900 febrile patients at a city same as present study P. vivax and P. falciparum mixed infections were seen in 367 (81.7%), 67 (14.9%) and 15, respectively. 17 We have observed male preponderance with male: female ratio (2:1), similar findings have been reported in earlier reports. 11

Fever was the most common symptom among all subtypes of malaria followed by vomiting (30.7%) and headache (20%). Fever was the single most important feature seen across all subtypes of malaria, which depends on the periodicity of rupture of schizonts. 17, 18, 19 Convulsions were reported in around 15% of our cases, which are in concordance (8-13%) with other studies. 18, 19 Convulsions are common in children compared to adults. Usually, they herald the onset of cerebral malaria. 20 Convulsions occur due to febrile seizure, cerebral oedema, and hypoglycaemia or as a part of cerebral malaria. 20, 21 Similarly, headache was seen in all forms of malaria ranging from 20-26% in present study. It is a common presenting complaint in malaria ranging from 18-66% of cases in different studies. 17, 19, 22 Cytokines, few anti-malarial drugs and post malaria neurologic syndrome are possible reasons for headache in malaria. 23 Though jaundice is one of the common findings in malaria, present study had only one case with clinical jaundice. This can be attributed to the fact that the district has one of the highest literacy rates and is a medical hub in the region. The people are very well aware of malaria and early referral and diagnosis is a possible explanation for the observation.

In pediatric falciparum malaria, the major complications include anemia, cerebral malaria and respiratory distress. 24 The complications in humans are attributed to its intra-erythrocytic phase of life cycle, leading to hematological changes like severe anemia, variations in leukocyte count function and coagulopathy. 6 The most common hematological changes seen in malaria infected individuals are significantly low platelets, leucocytes, erythrocytes and hemoglobin levels. 6, 25, 26, 27, 28 Similarly, in our study population we have observed that the falciparum group showed significant low platelets, low haemoglobin in mixed malaria group (Table 2). In mixed malaria, we have seen with decreased levels of RBC, haemoglobin count, reduced packed cell volume, mean corpuscular volume and mean corpuscular haemoglobin. Our patients had leucocytosis in vivax malaria group which has been reported in other study, 25 in contrary to some studies demonstrating to leukopenia. 29 Other leucocyte changes observed were increased neutrophil and monocyte counts in vivax and mixed malaria group, respectively as explained in various studies. 25, 26, 27, 28, 30

From a mechanistic view point, these derangements in the leucocytes are due to activation of bone marrow to produce and release more leucocytes and reduced lysis at the periphery. 25 Thrombocytopenia was noted among all the groups and it was significantly low compared to controls. Severe thrombocytopenia is the common complication especially in paediatric malaria cases 31. Various studies across Indian subcontinent have documented this complication but need for platelet transfusion was extremely rare. 19, 31, 32 Though exact aetiology for this is not known it is attributed to both immunological and non-immunological destruction of platelets. 33 Demonstrations of Plasmodium vivax within platelets by electron microscopy have been postulated as direct lytic effect of the parasite on the platelets. 34 Oxidative stress induced thrombocyte destruction is also postulated aetiology. 35

At molecular level, the production of cytokines like tumor necrosis factor (TNF) and interleukins is responsible for the derangement in the haematological parameters. These molecules in turn cause increased synthesis of C reactive protein (CRP), an acute phase inflammatory protein from liver, this explains the increased CRP in our study population. 36 However, CRP had a better correlation with infective state than ESR as it was significantly elevated in all groups. Though studies have noted strong linear trends regarding increasing CRP and severity of malaria no such conclusion could be drawn in present study. 37, 38

In malaria, the liver function is deranged with hyperbilirubinemia and increased aminotransferase enzymes. 11, 39, 40 The bilirubin levels were significantly increased in mixed malaria and increased liver enzymes in falciparum malaria. The suggested pathophysiological is the increased hemolysis of infected of RBC with cholestasis and hepatitis. Similarly, acute renal failure in malaria has been reported to be in as many of 60% cases. 41 Acute renal failure is may be seen in 80.9% and 11.7% in patients with P. falciparum and P.vivax, respectively. 42 On contrary, we have observed acute renal failure in mixed malaria group accompanied with hyponatremia, hypokalemia. No mortality was documented in present study, which can be attributed to early diagnosis & referral with less prevalence of HIV and malnourishment among children in our study population which are important contributing factors of mortality in malaria.

Conclusion

In conclusion, the change in clinico-laboratory parameters in various group of malaria infected paediatric population was studied. The most common derangement was seen in haemoglobin, platelets, PCV, MCH, blood urea, electrolytes and liver function parameters. These parameters can be used along with clinical features to consider malaria as differential diagnosis when a paediatric patients present with pyrexia of unknown origin, especially in malaria endemic area presents. The limitations of the study is that it’s a retrospective study with no details of the general health status of the children, previous episodes of malaria infection which has effect on the various parameters studied.

Source of Funding

None.

Conflict of Interest

None.

References

1 

B Singh LK Sung Ad Matusop B Singh A Radhakrishnan SSG Shamsul A large focus of naturally acquired Plasmodium knowlesi infections in human beingsLancet20043639414101724

2 

World Health Organisation: World Malaria Report 2010Geneva: World Health OrganizationGeneva, Sweden

4 

Anonymous2019https://www.malariasite.com/malaria-in-karnataka[Last Updated: Feb 13, 2019]

5 

S Bakhubaira Hematological parameters in severe complicated Plasmodium falciparum malaria among adults in AdenTurk J Haematol20133043949

6 

KS Akinosoglou EE Solomou CA Gogos Malaria: A haematological diseaseHematology201217210614

7 

I Ullah MU Ali S Ali A Rafiq Z Sattar S Hussain Hematological Profile of Patients Having Malaria-positive Peripheral Blood Smears: A Cross-sectional Study at a Diagnostic Research Center in Khyber Pakhtunkhwa, PakistanCureus2018109e337610.7759/cureus.3376

8 

K Kayentao LS Florey J Mihigo Impact evaluation of malaria control interventions on morbidity and all-cause child mortality in Mali, 2000-2012Malar J200017142410.1186/s12936-018-2573-1

9 

E Eckert LS Florey JE Tongren SR Salgado A Rukundo JP Habimana Impact Evaluation of Malaria Control Interventions on Morbidity and All-Cause Child Mortality in Rwanda, 2000-2010Am J Trop Med Hyg2000973_Suppl99110

10 

AK Rowe SY Rowe RW Snow EL Korenromp RM Joanna A Schellenberg The burden of malaria mortality among African children in the year 2000Int J Epidemiol2006353691704

11 

N Nagaraj PK Berwal A Srinivas P Prakash MS Ramesh Berwala Correlation of hepatorenal dysfunction in pediatricmalariaTrop Parasitol201882837

12 

RE Cibulskis P Alonso J Aponte Global progress 2000 - 2015 and future challengesInfect Dis Poverty2009516110.1186/s40249-016-0151-8

13 

13.WHO Malaria Policy Advisory Committee and Secretariat. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of sixth biannual meeting (September 2014)Malar J20141410710.1186/s12936-015-0623-5

14 

14.WHO Malaria Policy Advisory Committee and Secretariat. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of eighth biannual meeting (September 2015)Malar J20151511710.1186/s12936-016-1169-x

15 

GC Mccord D Conley JD Sachs Malaria ecology, child mortality & fertilityEcon Hum Biol20172411710.1016/j.ehb.2016.10.011

16 

S Kumar BV Rajesh K Arun A Muktha D Suman V Navya Malarial trend in Dakshina Kannada, Karnataka An epidemiological assessment from 2004 to 2013Indian J Health Sci Biomed Res201582914

17 

KK Dayanand K Punnath V Chandrashekar RN Achur SB Kakkilaya SK Ghosh Malaria prevalence in Mangaluru city area in the southwestern coastal region of IndiaMalar J201716149210.1186/s12936-017-2141-0

18 

HM Meena BS Sharma ML Gupta A Sharma R Choudhary P Sharma6 Clinico-laboratorical spectrum of malaria in children: Emerging new trendsCurr Pediatr Res20172133848

19 

M Kumari R Ghildiyal Clinical Profile of Plasmodium vivax Malaria in Children and Study of Severity Parameters in relation to Mortality: A Tertiary Care Centre Perspective in Mumbai, IndiaMalar Res Treat201476565710.1155/2014/765657

20 

SA Zaki P Shanbag Atypical manifestations of MalariaRes Rep Trop Med2011292210.2147/RRTM.S13431

21 

RE Phillips T Solomon Cerebral Malaria in childrenLancet19903368727135560

22 

S A Agrawal A clinical and laboratory profile of 100 cases of childhood malaria in a Private Teaching hospital in Northern IndiaJ Med Dental Sci Res201631115

23 

V Wiwanitkit Headache and malaria: A brief reviewActa Neurol Taiwan2009181569

24 

TE Kwenti TDB Kwenti A Latz LA Njunda T Nkuo-Akenji Epidemiological and clinical profile of paediatric malaria: a cross sectional study performed on febrile children in five epidemiological strata of malaria in CameroonBMC Infect Dis20171749910.1186/s12879-017-2587-2

25 

RN Maina D Walsh C Gaddy G Hongo J Waitumbi L Otieno Impact of Plasmodium falciparum infection on haematologicalparameters in children living in Western KenyaMalar J20109Suppl 3S410.1186/1475-2875-9-S3-S4

26 

ME Vanwolfswinkel K Vliegenthart-Jongbloed MM Melo, PC Wever MB McCall R Koelewijn Predictive value of lymphocytopenia and the neutrophil-lymphocyte count ratio for severe imported malariaMalar J20131210110.1186/1475-2875-12-101

27 

GM Warimwe LM Murungi G Kamuyu GM Nyangweso J Wambua V Naranbhai The ratio of monocytes to lymphocytes in peripheral blood correlates with increased susceptibility to clinical malaria in Kenyan childrenPLoS One2013825732010.1371/journal.pone.0057320

28 

P Gerardin C Rogier AS Ka P Jouvencel V Brousse P Imbert Prognostic value of thrombocytopenia in African children with falciparum malariaAm J Trop Med Hyg200266668691

29 

M Kotepui B Phunphuech N Phiwklam C Chupeerach S Duangmano Effect of malarial infection on haematological parameters in population near Thailand-Myanmar borderMalar J20141321810.1186/1475-2875-13-218

30 

RG Kini J Chandrashekar Parasite and the circulating Pool Characterisation of leucocyte number and Morphology in MalariaJ Clin Diagn Res2016105448

31 

D Yadav J Chandra S Aneja Clinical Profile of Severe Malaria in North Indian ChildrenIndian J Pediatr2012794483487

32 

S Nandwani A Pande M Saluja Clinical Profile of Severe Malaria: Study from tertiary care centre in north IndiaJ Parasit Dis2014381115

33 

S Looaresuwan JG Davis DL Allen Thrombocytopenia in malariaSoutheast Asian J Trop Med Public Health19922314450

34 

LF Fajardo C Tallent Malarial parasites within human plateletsJAMA1974229912057

35 

O Erel H Vural N Aksoy G Aslan M Ulukanligil Oxidative stress of platelets and thrombocytopenia in patients with vivax malariaClin Biochem20013443414

36 

SN Wickramasinghe SH Abdalla Blood and bone marrow changes in malariaBaillieres Best Pract Res Clin Haematol20001322779

37 

BB Andrade A Reis-Filho SM Souza-Neto Severe Plasmodium vivax malaria exhibits marked inflammatory imbalanceMalar J2010911310.1186/1475-2875-9-13

38 

BO Sarfo A Hahn NG Schwarz A Jaeger N Sarpong The usefulness of C-reactive protein in predicting malaria parasitemia in a sub-Saharan African regionPLOS ONE2018138e020169310.1371/journal.pone.0201693

39 

World Health Organization. Severe malariaTrop Med Int Health201419s17131

40 

DK Kochar P Singh P Agarwal SK Kochar R Pokharna PK Sareen Malarial hepatitisJ Assoc Physicians India200351106972

41 

KS Chugh V Sitprija V Jha Acute renal failure in tropical countriesAcute renal failure in tropical countriesElsevier1998

42 

S Kumar JE Epstein TL Richie Vaccines against asexual stage malaria parasitesChem Immunol2002802628610.1159/000058849



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 28-11-2023

Accepted : 22-12-2023


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijmmtd.2023.044


Article Metrics






Article Access statistics

Viewed: 533

PDF Downloaded: 118



Medical Abbreviation List